AngioDynamics (ANGO) Q3 2025 Earnings Transcript

Core Insights - AngioDynamics reported strong financial performance for the third quarter of fiscal year 2025, with total worldwide revenue reaching $72 million, reflecting a year-over-year growth of over 9% [5][18]. - The company has increased its guidance for total revenue, MedTech growth, gross margin, adjusted EBITDA, and adjusted EPS for the fiscal year 2025, indicating confidence in its operational strategy and market position [6][30]. Financial Performance - Total revenue for the third quarter was $72 million, with MedTech segment revenue growing by 22% to $31.3 million, while the Med Device segment saw a slight increase of 0.9% to $40.7 million [5][18]. - Adjusted EBITDA was reported at $1.3 million, a significant improvement from a loss of $3.6 million in the prior year [25]. - The adjusted net loss was $3.1 million, or an adjusted loss per share of $0.08, improving from a loss of $6.5 million or $0.16 per share in the same quarter last year [24]. Product Performance - The Auryon platform generated $13.9 million in revenue, growing 17.3% year-over-year, marking 15 consecutive quarters of double-digit growth [18]. - Mechanical Thrombectomy revenue, including AlphaVac and AngioVac, increased by 46.7% year-over-year, with AlphaVac revenue soaring by 161.4% [19]. - NanoKnife revenue reached $6.3 million, a 5.3% increase, with disposable revenue growing by 16.2% [19]. Strategic Outlook - The company expects revenue for fiscal 2025 to be in the range of $285 million to $288 million, representing growth of 5.3% to 6.4% over fiscal year 2024 [29]. - MedTech net sales are projected to grow between 14% to 16%, while Med Device net sales are expected to remain flat [30]. - The company is focused on increasing penetration in the hospital market for Auryon and expanding its sales force for AlphaVac and AngioVac to drive further growth [32][47]. Research and Development - R&D expenses were $6.9 million, or 9.6% of sales, down from $8.1 million or 12.2% of sales a year ago, reflecting a commitment to long-term growth in the MedTech segment [23]. - The AMBITION BTK trial is set to evaluate clinical outcomes for Auryon, with enrollment expected to begin in the next quarter [53]. Market Position - The company is well-positioned with a strong balance sheet, reporting $44.8 million in cash and cash equivalents as of February 28, 2025 [25]. - AngioDynamics is focused on driving sustainable, profitable growth through its innovative product portfolio and strategic market initiatives [35][58].